Key Findings
Resilience has announced a $750 million investment in a new pharmaceutical manufacturing site in Ohio, deepening its strategic partnership with Eli Lilly, with the goal of increasing the U.S. supply of medicines. This substantial investment expands Resilience’s broad range of Contract Development and Manufacturing Organization (CDMO) services, including biologics drug substance, cell-based therapies, and aseptic fill-finish manufacturing for both small and large molecules. This marks a critical step towards strengthening the domestic manufacturing ecosystem and enhancing the stability of the essential medicine supply chain within the U.S.
Technical/Clinical Details
The manufacturing services provided by Resilience are founded on cutting-edge technology and stringent quality standards. For biologics drug substance manufacturing, the company offers integrated support for complex processes from cell culture to purification and formulation. Cell-based therapy manufacturing, a personalized treatment approach, necessitates advanced cell manipulation, gene transduction, and production in sterile environments. Aseptic fill-finish manufacturing, the final filling of sterile products like injectables, requires strict GMP (Good Manufacturing Practice) regulations and state-of-the-art isolator technology. The $750 million investment is aimed at dramatically increasing production capacity in these areas, specifically through the introduction of automation, digitalization, and continuous manufacturing technologies to further enhance manufacturing efficiency and quality. This will enable Resilience to meet diverse scale needs, from clinical trial stages to commercial production.
Background & Context
The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, leading governments worldwide to prioritize strengthening domestic manufacturing capabilities. The U.S. government has also promoted policies to encourage domestic production of Essential Medicines and reduce reliance on overseas supply chains. Major pharmaceutical companies like Eli Lilly are actively forming partnerships with advanced CDMOs like Resilience to complement their in-house manufacturing capabilities and diversify risks. This trend is driven by the accelerated development of new modalities such as biologics and cell/gene therapies, and the increasing demand for the specialized expertise and large-scale facilities required to manufacture these complex therapeutics.
Strategic Significance & Outlook
This strategic investment by Resilience and Eli Lilly will significantly bolster U.S. pharmaceutical manufacturing capacity and contribute to stabilizing the medicine supply. Particularly, the expansion of domestic manufacturing capabilities for biologics and cell therapies will enable these groundbreaking treatments to reach more patients more quickly. This move also serves as preparation for future pandemics and geopolitical risks, potentially becoming a model for enhancing the resilience of the entire pharmaceutical supply chain. Furthermore, this investment is expected to generate jobs and foster economic growth in Ohio, bringing benefits to the local community.
Source: https://resilience.com/news/resilience-and-lilly-invest-750-million
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments